A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.

Balazs HalmosThomas BurkeChrysostomos KalyvasRalph InsingaKristel VandormaelAndrew FredericksonBilal Piperdi

Published in: Cancers (2020)

These MAIC results suggest that pembrolizumab + chemotherapy leads to a greater clinical benefit vs nivolumab + ipilimumab in patients with PD-L1 TPS ≥1% across multiple endpoints.

Keyphrases

advanced non small cell lung cancer
small cell lung cancer
locally advanced
squamous cell carcinoma
epidermal growth factor receptor
chemotherapy induced
rectal cancer
brain metastases
tyrosine kinase